APA
Wallentin L., Becker R. C., Cannon C. P., Held C., Himmelmann A., Husted S., James S. K., Katus H. A., Mahaffey K. M., Pieper K. S., Storey R. F., Steg P. G. & Harrington R. A. (20150512). No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. : International journal of cardiology.
Chicago
Wallentin Lars, Becker Richard C, Cannon Christopher P, Held Claes, Himmelmann Anders, Husted Steen, James Stefan K, Katus Hugo A, Mahaffey Kenneth M, Pieper Karen S, Storey Robert F, Steg Philippe Gabriel and Harrington Robert A. 20150512. No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. : International journal of cardiology.
Harvard
Wallentin L., Becker R. C., Cannon C. P., Held C., Himmelmann A., Husted S., James S. K., Katus H. A., Mahaffey K. M., Pieper K. S., Storey R. F., Steg P. G. and Harrington R. A. (20150512). No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. : International journal of cardiology.
MLA
Wallentin Lars, Becker Richard C, Cannon Christopher P, Held Claes, Himmelmann Anders, Husted Steen, James Stefan K, Katus Hugo A, Mahaffey Kenneth M, Pieper Karen S, Storey Robert F, Steg Philippe Gabriel and Harrington Robert A. No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. : International journal of cardiology. 20150512.